Ad-SGE-REIC
Malignant Glioma
Phase 1/2aTrial Completed (per website update)
Key Facts
Indication
Malignant Glioma
Phase
Phase 1/2a
Status
Trial Completed (per website update)
Company
About Momotaro-Gene
A Japanese biotech developing REIC/Dkk-3 gene therapy for solid tumors, with a lead program in malignant glioma.
View full company profile